Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 7/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.33 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.33 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3489282 | 0.88 | NOS2 (0.35) | NOS2NOS3NOS1ELANEPRCP | |
| SCHEMBL8440321 | 0.86 | SLC1A1 (0.39) | GRIK1GRIK2NOS2NOS3NOS1 | |
| SCHEMBL23757368 | 0.85 | SLC1A1 (0.38) | GRIK1GRIK2NOS2NOS3NOS1 | |
| Serine SCHEMBL181142 | 0.83 | NOS2 (0.32) | NOS2NOS3NOS1ELANE | |
| SCHEMBL3003565 | 0.80 | GRIK1 (0.41) | GRIK1GRIK2NOS2NOS3NOS1 | |
| SCHEMBL7536202 | 0.79 | NOS2 (0.35) | NOS2NOS3NOS1ELANEPRCP | |
| SCHEMBL2043828 | 0.79 | NOS2 (0.37) | GRIK1GRIK2NOS2NOS3NOS1 | |
| SCHEMBL10940484 | 0.78 | CTSC (0.45) | ELANECYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL11558601 | 0.78 | PRCP (0.34) | NOS2ELANEPRCPMEN1KMT2A | |
| SCHEMBL302682 | 0.78 | NOS2 (0.41) | NOS2NOS3NOS1ELANEPRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0514509-B1 | COMPOSITION AND ITS PREPARATION PROCESS USING ANTIGEN CONJUGATED TO ENZYMATIC ACTIVITY FOR IMMUNOLOGICAL DIAGNOSIS AND CHAGAS' DISEASE IMMUNOLOGICAL DIAGNOSIS KITS, FOR INDIVIDUAL AND EPIDEMIOLOGICAL APPLICATION, BASED ON THAT COMPOSITION | FUNDACAO OSWALDO CRUZ (BR) | 2000-09-20 | — | — | EP | claimed |
| US-5013659-A | Hybrid to resist sulfonylureas | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-05-07 | — | — | US | claimed |
| US-20240018261-A1 | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS ALTERED AFFINITIES FOR FcyRActivating and FcyRInhibiting | MACROGENICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11787871-B2 | Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for FcgammaRactivating and FegammaRinhibiting | MACROGENICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-113528484-B | nCas3 single-stranded endonuclease and application thereof | 湖北大学 | 2022-02-25 | — | — | CN | disclosed |
| CN-113528484-A | nCas3 single-stranded endonuclease and application thereof | 湖北大学 | 2021-10-22 | — | — | CN | disclosed |
| EP-1587540-B1 | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME | MACROGENICS INC (US) | 2021-09-15 | — | — | EP | disclosed |
| US-20200392245-A1 | Methods for the Treatment of Disease Using Immunoglobulins Having Fc Regions with Altered Affinities for FcgammaRactivating and FcgammaRinhibiting | MACROGENICS, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-10711069-B2 | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting | MACROGENICS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| CN-110291196-A | Thermostable reverse transcriptase mutants | 宝生物工程株式会社 | 2019-09-27 | — | — | CN | disclosed |
| US-20180009902-A1 | Methods for the Treatment of Disease Using Immunoglobulins Having Fc Regions with Altered Affinities for FcgammaRactivating and FcgammaRinhibiting | MACROGENICS, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| US-20070036799-A1 | Recombinant immunoglobulins to mediate cytotoxicity and treat cell proliferative disorders; immunotherapy | MACROGENICS, INC. | 2007-02-15 | — | — | US | disclosed |
| WO-2006088494-A2 | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT FC REGIONS AND METHODS OF USING THE SAME | MACROGENICS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060134709-A1 | Engineering Fc antibody regions to confer effector function | MACROGENICS, INC. | 2006-06-22 | — | — | US | disclosed |
| US-20050064514-A1 | Identification and engineering of antibodies with variant Fc regions and methods of using same | MACROGENICS, INC. | 2005-03-24 | — | — | US | disclosed |
| US-20050037000-A1 | A breast, ovarian, prostate, cervical, or pancreatic carcinoma antigen with at least one amino acid modification relative to a wild-type Fc region and that binds Fc gamma RIIA with a greater affinity; anticarcinogenic, antiinflammatory and antiarthritic agents | MACROGENICS, INC. | 2005-02-17 | — | — | US | disclosed |
| EP-0514509-B1 | COMPOSITION AND ITS PREPARATION PROCESS USING ANTIGEN CONJUGATED TO ENZYMATIC ACTIVITY FOR IMMUNOLOGICAL DIAGNOSIS AND CHAGAS' DISEASE IMMUNOLOGICAL DIAGNOSIS KITS, FOR INDIVIDUAL AND EPIDEMIOLOGICAL APPLICATION, BASED ON THAT COMPOSITION | FUNDACAO OSWALDO CRUZ (BR) | 2000-09-20 | — | — | EP | disclosed |
| EP-0314184-B1 | Expression plasmids | BRISTOL MYERS SQUIBB CO (US) | 1995-12-13 | — | — | EP | disclosed |
| CN-1061515-A | PROCESS OF ORANGE PASTE FOODSTUFFS | BEI JUHUA (CN) | 1992-06-03 | — | — | CN | disclosed |
| EP-0314184-A1 | Expression plasmids | Bristol-Myers Squibb Company (US) | 1989-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050064514-A1 | Identification and engineering of antibodies with variant Fc regions and methods of using same | FCGR1A, FCGR2A, FCGR3B | GRIK1 2395/4885GRIK2 2350/4885NOS2 2490/4885 |
| US-20050037000-A1 | A breast, ovarian, prostate, cervical, or pancreatic carcinoma antigen with at least one amino acid modification relative to a wild-type Fc region and that binds Fc gamma RIIA with a greater affinity; anticarcinogenic, antiinflammatory and antiarthritic agents | FCGR1A, FCGR2A, FCGR3B | GRIK1 3241/4885GRIK2 3660/4885NOS2 2911/4885 |
| US-20060134709-A1 | Engineering Fc antibody regions to confer effector function | FCGR2A, FCGR3B, FCGR1A | GRIK1 3402/4885GRIK2 3121/4885NOS2 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.